NCT05213884CompletedPhase 2
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck squamous cell carcinoma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- First submitted
- 16 Jan 2022
- Start date
- 1 Jan 2022
- Primary completion date
- 8 Feb 2026
- Lead sponsor
- Chongqing University Cancer Hospital
- Diseases
- Head and neck cancer
- NCT number
- NCT05213884
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 39
- From 1 Jan 2022 to the primary completion date, 8 Feb 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.
- Has received a live vaccine within 4 weeks of planned start of study therapy.
Other illness
- Have a history of immunodeficiency, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation.
- Active autoimmune disease (Such as type I diabetes, vitiligo, psoriasis, patients who do not need immunosuppressive drugs do not need to be excluded).
- Has a history of psychiatric substance abuse, alcoholism, or drug addiction.
- Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive.
Other
- Has abnormal thyroid function, and the thyroid function cannot be maintained normal despite medical treatment.
- Pregnancy or breast feeding.
Who the study is looking for
- Males and females ≥18 years of age.
- ECOG Performance Status 0 or 1.
- Histological diagnosis of squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, larynx or nasal sinus.
- Stage III, IVa, IVb (according to the 8th AJCC edition); Stage III for HPV positive oropharyngeal disease.
- Inoperable or refused surgery; eligible for definitive concurrent chemoradiotherapy.
- With measurable target lesions by CT or MRI.
- Adequate bone marrow function.
- Adequate renal and liver function.
- Pregnancy test (for patients of childbearing potential) negative at screening.
- Signed Written Informed Consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chongqing University Cancer Hospital Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| The Affiliated Hospital of Southwest Medical University Coordinator of this site? Confirm its status | Luzhou | China | Unknown status |
| Chongqing University Three Gorges Hospital Coordinator of this site? Confirm its status | Wanzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.